Zhouyi Wang
Xuzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Aberrant expression of triggering receptor expressed on myeloid cell-1 is involved in the immunopathological mechanism of myasthenia gravis.
Journal: Autoimmunity
Published: January 27, 2026
BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares.
Journal: Science advances
Published: January 02, 2026
A pilot study of the immunological profile and efficacy of rituximab in muscle-specific kinase antibody-positive myasthenia gravis.
Journal: Frontiers in immunology
Published: May 06, 2025
Efgartigimod as a fast-acting treatment in generalized very-late-onset myasthenia gravis.
Journal: Frontiers in immunology
Published: February 19, 2025
Targeting NF-kappaB-inducing kinase shapes B-cell homeostasis in myasthenia gravis.
Journal: Journal of neuroinflammation
Published: November 14, 2024
Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report.
Journal: Journal of neurology
Published: February 28, 2024
Increased serum interleukin-41 correlates with disease severity in myasthenia gravis.
Journal: International immunopharmacology
Published: February 07, 2024
Rescue treatment with add-on efgartigimod in a patient with impending myasthenic crisis: a case report.
Journal: Therapeutic advances in neurological disorders
Published: January 12, 2024
Refractory generalized myasthenia gravis treated successfully with telitacicept: two cases report.
Journal: Journal of neurology
Published: August 27, 2023
Macrophage migration inhibitory factor: A noval biomarker upregulates in myasthenia gravis and correlates with disease severity and relapse.
Journal: Cytokine
Published: August 03, 2023
Last Updated: 09/26/2026